<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">2983306R</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3565</journal-id>
<journal-id journal-id-type="nlm-ta">Epilepsia</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsia</journal-id>
<journal-title-group>
<journal-title>Epilepsia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0013-9580</issn>
<issn pub-type="epub">1528-1167</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28675559</article-id>
<article-id pub-id-type="pmc">5604891</article-id>
<article-id pub-id-type="doi">10.1111/epi.13785</article-id>
<article-id pub-id-type="manuscript">NIHMS870184</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Barker-Haliski</surname>
<given-names>Melissa L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Löscher</surname>
<given-names>Wolfgang</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>H. Steve</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">¶</xref>
<xref ref-type="author-notes" rid="FN2">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Galanopoulou</surname>
<given-names>Aristea S.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">¶</xref>
<xref ref-type="author-notes" rid="FN2">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA</aff>
<aff id="A2">
<label>2</label>Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany</aff>
<aff id="A3">
<label>3</label>Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Laboratory of Developmental Epilepsy, Bronx NY USA</aff>
<author-notes>
<corresp id="FN1"><label>¶</label>Corresponding authors: Aristea S. Galanopoulou, MD PhD, Professor, Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, 1410 Pelham Parkway South, Kennedy Center Rm 306, Bronx NY 10461, USA, Phone: 718-430-3791; Fax: 718-430-8899, <email>aristea.galanopoulou@einstein.yu.edu</email>. H. Steve White, PhD, Professor and Chair, Department of Pharmacy, School of Pharmacy, University of, Washington, Health Sciences Building H-375X, 1959 NE Pacific Street, Box 357630, Seattle, WA 98195-7630, USA, Phone: 206-543-3782; Fax: 206-543-3835, <email>hswhite@uw.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>#</label>
<p>HSW and ASG have contributed equally as senior authors in this manuscript.</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Disclosure</bold>
</p>
<p>We have no conflicts of interest in regards to this manuscript. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>58</volume>
<issue>Suppl 3</issue>
<fpage>39</fpage>
<lpage>47</lpage>
<!--elocation-id from pubmed: 10.1111/epi.13785-->
<abstract>
<p id="P1">Animal models have provided a wealth of information on mechanisms of epileptogenesis and comorbidogenesis and have significantly advanced our ability to investigate the potential of new therapies. Processes implicating brain inflammation have been increasingly observed in epilepsy research. Here, we discuss the progress on animal models of epilepsies and comorbidities that inform us on the potential role of inflammation in epileptogenesis and comorbidity pathogenesis in rodent models of West syndrome and the Theiler’s murine encephalomyelitis virus (TMEV) mouse model of viral encephalitis-induced epilepsy.</p>
<p id="P2">Rat models of infantile spasms were generated in rat pups after right intracerebral injections of pro-inflammatory compounds (lipopolysaccharides with or without doxorubicin, or cytokines) and were longitudinally monitored for epileptic spasms and neurodevelopmental and cognitive deficits. Anti-inflammatory treatments were tested after the onset of spasms. The TMEV mouse model was induced with intracerebral administration of TMEV and prospective monitoring for handling-induced seizures or seizure susceptibility, as well as long-term evaluations of behavioral comorbidities of epilepsy.</p>
<p id="P3">Inflammatory processes are evident in both models and are implicated in the pathogenesis of the observed seizures and comorbidities. A common feature of these models, based on the data so far available, is their pharmacoresistant profile.</p>
<p id="P4">The presented data support the role of inflammatory pathways in epileptogenesis and comorbidities in two distinct epilepsy models. Pharmacoresistance is a common feature of both of these inflammation-based models. Utilization of these models may facilitate the identification of age-specific, syndrome- or etiology- specific therapies for the epilepsies and attendant comorbidities, including the drug resistant forms.</p>
</abstract>
<kwd-group>
<kwd>infantile spasms</kwd>
<kwd>infection</kwd>
<kwd>encephalitis</kwd>
<kwd>therapies</kwd>
<kwd>cytokines</kwd>
<kwd>viral infection</kwd>
<kwd>comorbidities</kwd>
<kwd>epilepsy</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>